These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 8141968)
1. Topoisomerase II mediated DNA lesions induced by acridine-4-carboxamide and 2-(4-pyridyl)quinoline-8-carboxamide. Woynarowski JM; McCarthy K; Reynolds B; Beerman TA; Denny WA Anticancer Drug Des; 1994 Feb; 9(1):9-24. PubMed ID: 8141968 [TBL] [Abstract][Full Text] [Related]
2. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. Poddevin B; Riou JF; Lavelle F; Pommier Y Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227 [TBL] [Abstract][Full Text] [Related]
3. Topoisomerase II-mediated DNA damage produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide and related acridines in L1210 cells and isolated nuclei: relation to cytotoxicity. Covey JM; Kohn KW; Kerrigan D; Tilchen EJ; Pommier Y Cancer Res; 1988 Feb; 48(4):860-5. PubMed ID: 2827887 [TBL] [Abstract][Full Text] [Related]
4. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Rowe TC; Chen GL; Hsiang YH; Liu LF Cancer Res; 1986 Apr; 46(4 Pt 2):2021-6. PubMed ID: 3004716 [TBL] [Abstract][Full Text] [Related]
5. Production of protein-associated DNA breaks by 10-[diethylaminopropylamino]-6-methyl-5H-pyrido[3',4':4,5]pyrrolo [2,3-g]isoquinoline in cultured L1210 cells and in isolated nuclei: comparison with other topoisomerase II inhibitors. Pierson V; Pierre A; Pommier Y; Gros P Cancer Res; 1988 Mar; 48(6):1404-9. PubMed ID: 2830964 [TBL] [Abstract][Full Text] [Related]
6. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine. Sorensen M; Sehested M; Jensen PB Mol Pharmacol; 1999 Mar; 55(3):424-31. PubMed ID: 10051525 [TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents. Gamage SA; Spicer JA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA J Med Chem; 1999 Jul; 42(13):2383-93. PubMed ID: 10395479 [TBL] [Abstract][Full Text] [Related]
8. Comparison of DNA-protein cross-links induced by 4'-(9-acridinylamino)-methanesulfon-m-anisidide and by gamma-radiation. Chiu SM; Xue LY; Friedman LR; Oleinick NL Cancer Res; 1989 Feb; 49(4):910-4. PubMed ID: 2912561 [TBL] [Abstract][Full Text] [Related]
9. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage. Marx G; Zhou H; Graves DE; Osheroff N Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321 [TBL] [Abstract][Full Text] [Related]
10. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Drake FH; Hofmann GA; Mong SM; Bartus JO; Hertzberg RP; Johnson RK; Mattern MR; Mirabelli CK Cancer Res; 1989 May; 49(10):2578-83. PubMed ID: 2540903 [TBL] [Abstract][Full Text] [Related]
12. Effects of the bifunctional antitumor intercalator ditercalinium on DNA in mouse leukemia L1210 cells and DNA topoisomerase II. Markovits J; Pommier Y; Mattern MR; Esnault C; Roques BP; Le Pecq JB; Kohn KW Cancer Res; 1986 Nov; 46(11):5821-6. PubMed ID: 3019538 [TBL] [Abstract][Full Text] [Related]
13. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells. Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions. Finlay GJ; Atwell GJ; Baguley BC Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026 [TBL] [Abstract][Full Text] [Related]
15. Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs. Epstein RJ; Smith PJ Cancer Res; 1988 Jan; 48(2):297-303. PubMed ID: 2825970 [TBL] [Abstract][Full Text] [Related]
16. Induction of topoisomerase II-mediated DNA cleavage by a protoberberine alkaloid, berberrubine. Kim SA; Kwon Y; Kim JH; Muller MT; Chung IK Biochemistry; 1998 Nov; 37(46):16316-24. PubMed ID: 9819224 [TBL] [Abstract][Full Text] [Related]
17. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA). Bridewell DJ; Finlay GJ; Baguley BC Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884 [TBL] [Abstract][Full Text] [Related]
18. Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells. Zwelling LA; Chan D; Hinds M; Mayes J; Silberman LE; Blick M Cancer Res; 1988 Dec; 48(23):6625-33. PubMed ID: 2846155 [TBL] [Abstract][Full Text] [Related]
19. Modulation of 4'-(9-acridinylamino)methanesulfon-m-anisidide-induced, topoisomerase II-mediated DNA cleavage by gossypol. Adlakha RC; Ashorn CL; Chan D; Zwelling LA Cancer Res; 1989 Apr; 49(8):2052-8. PubMed ID: 2539251 [TBL] [Abstract][Full Text] [Related]
20. Effect of cell proliferation and chromatin conformation on intercalator-induced, protein-associated DNA cleavage in human brain tumor cells and human fibroblasts. Zwelling LA; Estey E; Silberman L; Doyle S; Hittelman W Cancer Res; 1987 Jan; 47(1):251-7. PubMed ID: 3024817 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]